急性呼吸衰竭患者中限时试验使用特征:前瞻性单中心观察性研究
该前瞻性12个月观察性队列研究在美国一家学术医疗中心开展,纳入176例接受有创机械通气≥48小时的急性呼吸衰竭成人ICU患者,由ICU医师识别限时试验(TLT)参与情况。36例(20.5%)参与TLT,中位TLT持续3.0天(IQR 3.0-4.5天)。TLT患者较非TLT患者年龄更高(67.4岁 vs 60.0岁,p<0.01)、Charlson共病指数更高(5.1 vs 3.8,p<0.01),SOFA评分相似(9.6 vs 9.5,p=0.93);TLT患者死亡或出院转临终关怀比例更高(80.6% vs 42.1%,p<0.05),ICU住院时间更短(中位5.7天 vs 10.3天,p<0.01)。作者认为TLT主要用于接近生命终末期的患者,但医生间差异大,需要证据指导最佳使用。
要点
- 176例急性呼吸衰竭接受有创机械通气≥48小时的成人ICU患者中,36例(20.5%)参与限时试验。
- 18名ICU主治医师中仅9名(50%)参与过至少1次限时试验,频率范围为所照护患者的0-39%。
- 限时试验中位持续3.0天(IQR 3.0-4.5天)。
- 限时试验患者死亡或出院转临终关怀比例80.6%,高于非限时试验患者的42.1%(p<0.05)。
- 限时试验患者ICU住院时间中位5.7天(IQR 4.0-9.0天),短于非限时试验患者的10.3天(IQR 5.5-14.5天)(p<0.01)。
适用人群与场景
- 美国一家学术医疗中心成人ICU中急性呼吸衰竭并接受有创机械通气≥48小时的患者。
- 研究纳入176例符合条件的患者。
诊断标准与关键阈值
- 限时试验(TLT)定义为临床医生、患者和家属共同制定的计划,使用生命维持治疗一段明确时间,之后根据患者反应决定继续以康复为目标还是转向舒适照护。
- TLT参与由患者的ICU医师识别。
研究设计与关键结果
- 研究类型:前瞻性12个月观察性队列研究,美国一家学术医疗中心,纳入176例急性呼吸衰竭接受有创机械通气≥48小时的成人ICU患者。
- 主要暴露:TLT参与,由ICU医师识别;36例(20.5%)参与TLT,中位TLT持续3.0天(IQR 3.0-4.5天)。
- 18名ICU主治医师中9名(50%)参与过至少1次TLT,频率范围为所照护患者的0-39%。
- TLT患者与非TLT患者比较:平均年龄67.4岁(sd 12.0) vs 60.0岁(sd 16.0),p<0.01;Charlson共病指数5.1(sd 2.2) vs 3.8(sd 2.6),p<0.01;SOFA评分9.6(sd 3.3) vs 9.5(sd 3.7),p=0.93。
- TLT患者死亡或出院转临终关怀比例80.6% vs 非TLT患者42.1%(p<0.05);ICU住院时间中位5.7天(IQR 4.0-9.0天) vs 10.3天(IQR 5.5-14.5天)(p<0.01)。
证据类型、等级与局限
- 证据类型:前瞻性单中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,TLT主要用于接近生命终末期的患者,但医生间使用差异大,需要证据指导最佳使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A time-limited trial (TLT) is a collaborative plan among clinicians, patients, and families to use life-sustaining therapy for a defined duration, after which the patient's response informs whether to continue care directed toward recovery or shift the focus toward comfort. TLTs are a promising approach to help navigate uncertainty in critical illness, yet little is known about their current use.
OBJECTIVES: To characterize TLT use in patients with acute respiratory failure (ARF).
DESIGN, SETTING, AND PARTICIPANTS: Prospective 12-month observational cohort study at an U.S. academic medical center of adult ICU patients with ARF receiving invasive mechanical ventilation for greater than or equal to 48 hours.
MAIN OUTCOMES AND MEASURES: Primary exposure was TLT participation, identified by patients' ICU physician. Patient characteristics, care delivery elements, and hospital outcomes were extracted from the electronic medical record.
RESULTS: Among 176 eligible patients, 36 (20.5%) participated in a TLT. Among 18 ICU attending physicians, nine (50%) participated in greater than or equal to 1 TLT (frequency 0-39% of patients cared for). Median TLT duration was 3.0 days (interquartile range [IQR], 3.0-4.5 d). TLT patients had a higher mean age (67.4 yr [sd, 12.0 yr] vs. 60.0 yr [sd, 16.0 yr]; p < 0.01), higher Charlson Comorbidity Index (5.1 [sd, 2.2] vs. 3.8 [sd, 2.6]; p < 0.01), and similar Sequential Organ Failure Assessment score (9.6 [sd, 3.3] vs. 9.5 [sd, 3.7]; p = 0.93), compared with non-TLT patients. TLT patients were more likely to die or be discharged to hospice (80.6% vs. 42.1%; p < 0.05) and had shorter ICU length of stay (median, 5.7 d [IQR, 4.0-9.0 d] vs. 10.3 d [IQR, 5.5-14.5 d]; p < 0.01).
CONCLUSIONS AND RELEVANCE: In this study, approximately one in five patients with ARF participated in a TLT. Our findings suggest TLTs are used primarily in patients near end of life but with substantial physician variation, highlighting a need for evidence to guide optimal use.
参考来源
- Moy JX, Law AC, Stalter LN, et al. Characterizing the Use of Time-Limited Trials in Patients With Acute Respiratory Failure: A Prospective, Single-Center Observational Study. Crit Care Explor. 2024. PMID: 39283228. doi:10.1097/CCE.0000000000001148
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。